Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00390234 · OUTCOME

Survival (Carcinosarcoma Group)

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma · Source last updated 2015-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 3 years

What was measured

Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.

Groups in this outcome

Treatment (Ziv-aflibercept)

Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Ziv-aflibercept)22

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Ziv-aflibercept)3.2Not reported1.4NAValue not reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Value not reached
        group Id
        OG000
        lower Limit
        1.4
        upper Limit
        NA
        value
        3.2
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV
    id
    OG000
    title
    Treatment (Ziv-aflibercept)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 3 years
title
Survival (Carcinosarcoma Group)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice